NDA 200732 · Pharmobedient
Zidovudine
Zidovudine · Oral
DiscontinuedLast checked: Nov 19, 2026Latest source record: Dec 27, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2011
Feb 23, 2011
Approved uses
1
Original approval plus efficacy supplements
Registered trials
497
105 Phase 3, 3 recruiting
FAERS reports
10,367
9,840 serious, 1,459 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- ZIDOVUDINE · ZIDOVUDINE 100MG · TABLET, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Zidovudine" as an intervention, any sponsor and status, largest first.
- A Study of Saquinavir Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected PatientsPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT00002382 · 4,000 participants
Drug: Saquinavir · For: HIV Infections
Sites: Nutley, New Jersey
- Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Resource-Limited CountriesPivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT01061151 · 3,747 participants · Start Mar 1, 2011 · Primary completion Sep 30, 2016
Drug: Zidovudine (ZDV); Nevirapine (NVP): Antepartum Mothers and 6 more · For: HIV Infections
Sites: Pune, India; Blantyre, Malawi; Lilongwe, Malawi · 14 sites in all
- Preventing Sexual Transmission of HIV With Anti-HIV DrugsPivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00074581 · 3,526 participants · Start Feb 2005 · Primary completion May 2015
Drug: Atazanavir; Didanosine and 8 more · For: HIV Infections
Sites: Boston, Massachusetts; Gaborone, Botswana; Nova Iguaçu, Brazil · 17 sites in all
- Extended Infant Post-exposure Prophylaxis With Antiretrovirals to Reduce Postnatal HIV TransmissionPivotal-lookingCompleted
Johns Hopkins Bloomberg School of Public HealthAcademic, hospital or other
NCT00115648 · 3,300 participants (planned) · Start Apr 2004 · Primary completion Aug 2007
Drug: Nevirapine; AZT and 3 more · For: HIV Infections
Sites: Blantyre, Malawi
- Safety and Efficacy of Zidovudine for Asymptomatic HIV-Infected IndividualsPivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00000736 · 3,200 participants
Drug: Zidovudine · For: HIV Infections
Sites: Los Angeles, California; Oakland, California; Palo Alto, California · 43 sites in all
- A Study of Zidovudine (AZT) Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Patients With Little or No Previous TreatmentPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT00002334 · 3,000 participants
Drug: Saquinavir; Zidovudine and 1 more · For: HIV Infections
Sites: Phoenix, Arizona; Sacramento, California; San Francisco, California · 26 sites in all
- Efficacy of Nevirapine Compared to ZDV + 3TC Administered in Labor and Again at Postdelivery in HIV Positive WomenPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT02181933 · 2,648 participants · Start Apr 1999 · Primary completion Jan 2001
Drug: Nevirapine; Zidovudine (ZDV) and 1 more · For: HIV Infections
- Breastfeeding, Antiretroviral, and Nutrition StudyPivotal-lookingCompleted
Centers for Disease Control and PreventionFederal agency
NCT00164736 · 2,369 participants · Start Mar 2004 · Primary completion Jan 2010
Drug: Maternal zidovudine/lamivudine/lopinavir-ritonavir; Infant nevirapine · For: HIV Infections
Sites: Lilongwe, Malawi
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- foetal exposure during pregnancy1,625
- virologic failure778
- drug resistance709
- anaemia617
- exposure during pregnancy588
- pathogen resistance585
- drug exposure during pregnancy580
- viral mutation identified567
- premature baby497
- maternal exposure during pregnancy428
- treatment failure420
- lipodystrophy acquired413
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 342 |
| 2005 | 319 |
| 2006 | 479 |
| 2007 | 447 |
| 2008 | 445 |
| 2009 | 480 |
| 2010 | 459 |
| 2011 | 347 |
| 2012 | 282 |
| 2013 | 298 |
| 2014 | 344 |
| 2015 | 534 |
| 2016 | 1,064 |
| 2017 | 902 |
| 2018 | 740 |
| 2019 | 607 |
| 2020 | 706 |
| 2021 | 405 |
| 2022 | 359 |
| 2023 | 357 |
| 2024 | 174 |
| 2025 | 136 |
| 2026 | 139 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Zidovudine (Zidovudine)
2024 spending
$169K
Beneficiaries
398
2,642 claims
Per beneficiary
$424
$0.73 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $298,564 |
| 2021 | $239,429 |
| 2022 | $235,499 |
| 2023 | $211,258 |
| 2024 | $168,652 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Half-dose zidovudine.
de Truchis P, Salmon D, Matheron S, et al. · Lancet 1991 · Clinical Trial, Comparative Study
- Zidovudine (AZT).
· Lancet 1987 · Clinical Trial, Editorial
- Zidovudine (Retrovir) update.
Rachlis AR · CMAJ 1990 · Clinical Trial, Guideline
- Concentration-controlled zidovudine therapy.
Fletcher CV, Acosta EP, Henry K, et al. · Clin Pharmacol Ther 1998 · Clinical Trial, Randomized Controlled Trial
- Zidovudine for symptomless HIV infection.
· Lancet 1990 · Clinical Trial, Editorial
- Zidovudine-induced fever.
Jacobson MA, McGrath MS, Joseph P, et al. · J Acquir Immune Defic Syndr (1988) 1989 · Case Reports, Clinical Trial
Sponsor: Pharmobedient
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.